Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established procedure for many acquired and congenital disorders of the hematopoietic system. A record number of 42 171 HSCT in 37 626 patients (16 030 allogeneic (43%), 21 596 autologous (57%)) were reported by 655 centers in 48 countries in 2015. Trends include continued growth in transplant activity over the last decade, with the highest percentage increase seen in middle-income countries but the highest absolute growth in the very-high-income countries in Europe. Main indications for HSCT were myeloid malignancies 9413 (25% 96% allogeneic), lymphoid malignancies 24 304 (67% 20% allogeneic), solid tumors 1516 (4% 3% allogeneic) and non-malignant disorders 2208 (6% 90% allogeneic). Remarkable is the decreasing use of allogeneic HSCT for CLL from 504 patients in 2011 to 255 in 2015, most likely to be due to new drugs. Use of haploidentical donors for allogeneic HSCT continues to grow: 2012 in 2015, a 291% increase since 2005. Growth is seen for all diseases. In AML, haploidentical HSCT increases similarly for patients with advanced disease and for those in CR1. Both marrow and peripheral blood are used as the stem cell source for haploidentical HSCT with higher numbers reported for the latter.

Impact of Donor Type in Patients with AML Given Allogeneic Hematopoietic Cell Transplantation After Low-Dose TBI-Based Regimen

“…Consequently, haplo-HCT is increasingly used in Europe while the use of CBT is declining (36). Several recent studies assessing the impact of donor type on transplantation outcomes have been reported (19,24,(37)(38)(39)(40)(41)(42)(43)(44).…”

Antimicrobial Resistance in Gram-Negative Rods Causing Bacteremia in Hematopoietic Stem Cell Transplant Recipients: Intercontinental Prospective Study of the Infectious Diseases Working Party of the European Bone Marrow Transplantation Group

“…All P values are 2 side the analyses were performed using the statistical software SAS version 9.4 ( Sixty-five HSCT centers from 25 countries reported data on 655 GNR episod 591 patients (1.1 episodes [range, [1][2][3][4] Abbreviations: allo, allogeneic; auto, autologous; βL/βLI, β-lactam/β-lactamase inhibitor; GVHD, g host disease; HSCT, hematopoietic stem cell transplant; ICU, intensive care unit.…”

Challenges to the Sustainability of the U.S. Public Cord Blood System

“…In recent years, the share of HPC transplants that used haploidentical sources has been rising (see Text Box 3 in Chapter Four), while the share of CBU transplants has fallen, both in the United States and abroad. 151 In this section, we explore the potential for further growth in the relative number of haploidentical HSC transplants, which might contribute to lower demand for cord blood and increasing financial pressure on CBBs. Investments in infrastructure and training that support haploidentical transplants and reduced investments in cord blood infrastructure and training may be self-perpetuating.…”